TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ARVN stock, giving a Buy rating on February 22.
Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Arvinas Holding Company’s promising clinical data and strategic development plans. The impressive median progression-free survival (mPFS) of 11.1 months reported for the combination of vepdeg and palbociclib (palbo) is significantly higher than the historical averages observed with other CDK4/6 and endocrine therapy combinations, which typically range around 4-5 months. The potential to maintain such efficacy at a lower palbo dosage in Phase III trials, while improving safety by reducing neutropenia rates, further strengthens the rationale for a positive outlook on the stock.
Furthermore, the ongoing Phase III VERITAC-3 trial’s adaptive design, which includes evaluating lower doses of palbociclib, is expected to optimize the treatment regimen early in the trial. This approach aims to maximize trial efficiency and minimize adverse effects. In conjunction with the strategic partnership with Pfizer, Arvinas is also exploring a first-line CDK4i combination treatment. These strategic moves, alongside the promising data from recent trials, underpin Tyler Van Buren’s Buy rating for Arvinas Holding Company.
Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, Travere Therapeutics, and Spyre Therapeutics. According to TipRanks, Van Buren has an average return of 3.8% and a 46.07% success rate on recommended stocks.
In another report released on February 22, Stifel Nicolaus also assigned a Buy rating to the stock with a $70.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arvinas Holding Company (ARVN) Company Description:
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
Read More on ARVN:
- Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- ARVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Arvinas CFO Sean Cassidy to Resign, Interim Successor Named
- Arvinas announces resignation of CFO Sean Cassidy
- Arvinas Announces Chief Financial Officer Transition
